CL2015001608A1 - Formulación en solución de anticuerpo humanizado anti-il-23p19; y uso de formulación para tratar enfermedad autoinmune, enfermedad inflamatoria o trastorno proliferativo, particularmente psoriasis. - Google Patents

Formulación en solución de anticuerpo humanizado anti-il-23p19; y uso de formulación para tratar enfermedad autoinmune, enfermedad inflamatoria o trastorno proliferativo, particularmente psoriasis.

Info

Publication number
CL2015001608A1
CL2015001608A1 CL2015001608A CL2015001608A CL2015001608A1 CL 2015001608 A1 CL2015001608 A1 CL 2015001608A1 CL 2015001608 A CL2015001608 A CL 2015001608A CL 2015001608 A CL2015001608 A CL 2015001608A CL 2015001608 A1 CL2015001608 A1 CL 2015001608A1
Authority
CL
Chile
Prior art keywords
formulation
humanized anti
proliferative disorder
antibody solution
treat autoimmune
Prior art date
Application number
CL2015001608A
Other languages
English (en)
Spanish (es)
Inventor
Ramesh S Kashi
Aniket Badkar
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50934859&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015001608(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of CL2015001608A1 publication Critical patent/CL2015001608A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CL2015001608A 2012-12-13 2015-06-10 Formulación en solución de anticuerpo humanizado anti-il-23p19; y uso de formulación para tratar enfermedad autoinmune, enfermedad inflamatoria o trastorno proliferativo, particularmente psoriasis. CL2015001608A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261737035P 2012-12-13 2012-12-13

Publications (1)

Publication Number Publication Date
CL2015001608A1 true CL2015001608A1 (es) 2015-10-30

Family

ID=50934859

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015001608A CL2015001608A1 (es) 2012-12-13 2015-06-10 Formulación en solución de anticuerpo humanizado anti-il-23p19; y uso de formulación para tratar enfermedad autoinmune, enfermedad inflamatoria o trastorno proliferativo, particularmente psoriasis.

Country Status (31)

Country Link
US (2) US20210188964A1 (cg-RX-API-DMAC7.html)
EP (1) EP2931313B1 (cg-RX-API-DMAC7.html)
JP (1) JP6266012B2 (cg-RX-API-DMAC7.html)
KR (1) KR102004585B1 (cg-RX-API-DMAC7.html)
CN (1) CN104870016B (cg-RX-API-DMAC7.html)
AU (1) AU2013359767B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015013540B1 (cg-RX-API-DMAC7.html)
CA (1) CA2894869C (cg-RX-API-DMAC7.html)
CL (1) CL2015001608A1 (cg-RX-API-DMAC7.html)
CY (1) CY1121895T1 (cg-RX-API-DMAC7.html)
DK (1) DK2931313T3 (cg-RX-API-DMAC7.html)
EA (1) EA034616B1 (cg-RX-API-DMAC7.html)
ES (1) ES2732861T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20191137T1 (cg-RX-API-DMAC7.html)
HU (1) HUE045668T2 (cg-RX-API-DMAC7.html)
IL (3) IL278295B2 (cg-RX-API-DMAC7.html)
LT (1) LT2931313T (cg-RX-API-DMAC7.html)
MX (1) MX357936B (cg-RX-API-DMAC7.html)
MY (1) MY187921A (cg-RX-API-DMAC7.html)
NZ (1) NZ708443A (cg-RX-API-DMAC7.html)
PE (1) PE20151524A1 (cg-RX-API-DMAC7.html)
PH (1) PH12015501296A1 (cg-RX-API-DMAC7.html)
PL (1) PL2931313T3 (cg-RX-API-DMAC7.html)
PT (1) PT2931313T (cg-RX-API-DMAC7.html)
RS (1) RS59057B1 (cg-RX-API-DMAC7.html)
SI (1) SI2931313T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201900414T1 (cg-RX-API-DMAC7.html)
TR (1) TR201909584T4 (cg-RX-API-DMAC7.html)
UA (1) UA117466C2 (cg-RX-API-DMAC7.html)
WO (1) WO2014093203A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201504408B (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI806150B (zh) 2014-11-07 2023-06-21 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
JP7179717B2 (ja) * 2017-03-31 2022-11-29 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 水性製剤及び注射器入り水性製剤、並びに、抗体タンパク脱凝集剤及び抗体タンパク脱凝集方法
MX2020009265A (es) * 2018-03-05 2020-10-01 Janssen Biotech Inc Metodos para tratar la enfermedad de crohn con un anticuerpo especifico anti-il23.
SG11202104166QA (en) * 2018-11-21 2021-05-28 Regeneron Pharma High concentration protein formulation
CN112334483B (zh) 2018-11-27 2022-05-10 信达生物制药(苏州)有限公司 抗IL-23p19抗体及其用途
US12493019B2 (en) 2019-02-20 2025-12-09 Amgen Inc. Methods of determining protein stability
AU2020279987A1 (en) 2019-05-23 2021-11-18 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
US20210070852A1 (en) * 2019-09-09 2021-03-11 Boehringer Ingelheim International Gmbh Anti-IL-23p19 Antibody Formulations
US11396541B2 (en) 2019-12-20 2022-07-26 Novarock Biotherapeutics, Ltd. Anti-interleukin-23 P19 antibodies and methods of use thereof
BR112022022919A2 (pt) * 2020-05-13 2022-12-20 Innovent Biologics Suzhou Co Ltd Formulação compreendendo o anticorpo anti-il-23p19, método para preparar o mesmo e uso do mesmo".
CA3183927A1 (en) 2020-05-21 2021-11-25 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
WO2025071362A1 (ko) * 2023-09-27 2025-04-03 삼성바이오에피스 주식회사 항-il-23 항체의 안정한 액상 제형

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2366706A1 (en) 1999-03-11 2000-09-14 Schering Corporation Mammalian cytokines; related reagents and methods
JP4505166B2 (ja) 1999-09-09 2010-07-21 シェーリング コーポレイション 哺乳動物インターロイキン−１２ｐ４０およびインターロイキンｂ３０、その組成物、抗体、薬学的組成物における使用
DE60235013D1 (de) 2001-07-25 2010-02-25 Facet Biotech Corp Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab
CA2466034C (en) * 2001-11-08 2012-12-18 Protein Design Labs, Inc. Stable aqueous pharmaceutical formulations of daclizumab antibodies
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
WO2004071517A2 (en) 2003-02-06 2004-08-26 Schering Corporation Uses of il-23 related reagents
DK2236154T3 (en) 2003-02-10 2018-06-25 Biogen Ma Inc IMMUNOGLOBULIN INFORMATION AND METHOD OF PREPARING IT
EP1601694B1 (en) 2003-03-10 2009-08-26 Schering Corporation Uses of il-23 antagonists; related reagents
BRPI0403964B8 (pt) * 2003-04-04 2021-05-25 Genentech Inc formulações líquidas estáveis, artigo manufaturado e uso dessas formulações para o tratamento de disfunção mediada por ige
WO2005079837A1 (en) 2004-02-17 2005-09-01 Schering Corporation Methods of modulating il-23 activity; related reagents
WO2005117967A2 (en) 2004-04-12 2005-12-15 Medimmune, Inc. Anti-il-9 antibody formulations and uses thereof
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
HRP20130400T1 (en) 2005-06-30 2013-06-30 Janssen Biotech, Inc. Anti-il-23 antibodies, compositions, methods and uses
SI1937721T1 (sl) 2005-08-25 2010-11-30 Lilly Co Eli Anti il protitelesa
DK1931710T3 (en) 2005-08-31 2017-04-03 Merck Sharp & Dohme CONSTRUCTED ANTI-IL-23 ANTIBODIES
DK2548577T3 (en) 2005-12-29 2017-03-13 Janssen Biotech Inc HUMAN ANTI-IL-23 ANTIBODIES, COMPOSITIONS, PROCEDURES AND APPLICATIONS
CA2655372A1 (en) 2006-06-13 2007-12-21 Zymogenetics, Inc. Il-17 and il-23 antagonists and methods of using the same
MX2009003982A (es) 2006-10-20 2009-04-27 Amgen Inc Formulaciones de polipeptido estables.
AU2008204901A1 (en) 2007-01-09 2008-07-17 Wyeth Anti-IL-13 antibody formulations and uses thereof
TWI426918B (zh) 2007-02-12 2014-02-21 Merck Sharp & Dohme Ｉｌ-２３拮抗劑於治療感染之用途
SG178804A1 (en) 2007-02-23 2012-03-29 Schering Corp Engineered anti-il-23p19 antibodies
US8293883B2 (en) * 2007-02-23 2012-10-23 Schering Corporation Engineered anti-IL-23P19 antibodies
EP2068923A4 (en) * 2007-03-30 2010-11-24 Medimmune Llc ANTIBODIES HAVING REDUCED DEAMIDATION PROFILES
US20090208492A1 (en) * 2007-06-14 2009-08-20 Elan Pharmaceuticals, Inc. Lyophilized Immunoglobulin Formulations and Methods of Preparation
WO2009114040A2 (en) 2007-09-28 2009-09-17 Centocor Ortho Biotech Inc. Anti-il-12/23p40 antibodies, epitopes, formulations, compositions, methods and uses
AR068723A1 (es) 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
ES2511844T3 (es) 2007-12-21 2014-10-23 F. Hoffmann-La Roche Ag Formulación de anticuerpo
SG191639A1 (en) * 2008-06-03 2013-07-31 Abbott Lab Dual variable domain immunoglobulins and uses thereof
AU2009288419B2 (en) * 2008-08-27 2015-08-06 Merck Sharp & Dohme Llc Lyophilized formulatons of engineered anti-IL-23p19 antibodies
EP2331090B1 (en) * 2008-09-19 2018-01-03 Pfizer Inc. Stable liquid antibody formulation
WO2010062896A1 (en) * 2008-11-28 2010-06-03 Abbott Laboratories Stable antibody compositions and methods for stabilizing same
KR20120110175A (ko) * 2009-12-29 2012-10-09 에프. 호프만-라 로슈 아게 항체 제제
DK2691112T3 (en) 2011-03-31 2018-07-30 Merck Sharp & Dohme STABLE FORMULATIONS OF ANTIBODIES AGAINST HUMAN PD (PROGRAMMED DEATH) 1- RECEPTOR AND RELATED TREATMENTS

Also Published As

Publication number Publication date
KR20150092763A (ko) 2015-08-13
IL307581A (en) 2023-12-01
AU2013359767B2 (en) 2018-04-05
RS59057B1 (sr) 2019-08-30
IL278295A (cg-RX-API-DMAC7.html) 2020-12-31
BR112015013540B1 (pt) 2021-04-27
MX357936B (es) 2018-07-31
PT2931313T (pt) 2019-07-10
US20150329632A1 (en) 2015-11-19
HUE045668T2 (hu) 2020-01-28
JP2016505572A (ja) 2016-02-25
KR102004585B1 (ko) 2019-07-26
DK2931313T3 (da) 2019-07-15
SMT201900414T1 (it) 2019-09-09
WO2014093203A1 (en) 2014-06-19
ZA201504408B (en) 2017-09-27
BR112015013540A8 (pt) 2018-04-17
IL278295B2 (en) 2024-03-01
EP2931313A1 (en) 2015-10-21
US20240239884A1 (en) 2024-07-18
MX2015007213A (es) 2016-08-03
ES2732861T3 (es) 2019-11-26
JP6266012B2 (ja) 2018-01-24
PL2931313T3 (pl) 2019-10-31
CY1121895T1 (el) 2020-10-14
IL239150A0 (en) 2015-07-30
UA117466C2 (uk) 2018-08-10
IL239150B (en) 2020-11-30
BR112015013540A2 (pt) 2017-11-14
EA034616B1 (ru) 2020-02-27
PH12015501296B1 (en) 2015-08-24
CA2894869C (en) 2021-06-15
TR201909584T4 (tr) 2019-07-22
LT2931313T (lt) 2019-09-25
CA2894869A1 (en) 2014-06-19
NZ708443A (en) 2018-05-25
IL278295B1 (en) 2023-11-01
CN104870016B (zh) 2018-05-08
HRP20191137T1 (hr) 2019-09-20
AU2013359767A1 (en) 2015-07-23
EP2931313A4 (en) 2016-08-03
EP2931313B1 (en) 2019-05-08
EA201591133A1 (ru) 2015-10-30
SI2931313T1 (sl) 2019-09-30
PH12015501296A1 (en) 2015-08-24
HK1215194A1 (en) 2016-08-19
PE20151524A1 (es) 2015-11-06
US20210188964A1 (en) 2021-06-24
MY187921A (en) 2021-10-28
CN104870016A (zh) 2015-08-26

Similar Documents

Publication Publication Date Title
CL2015001608A1 (es) Formulación en solución de anticuerpo humanizado anti-il-23p19; y uso de formulación para tratar enfermedad autoinmune, enfermedad inflamatoria o trastorno proliferativo, particularmente psoriasis.
BR112014018136A2 (pt) anticorpos ou uso e método para determinar
BR112014032193A2 (pt) métodos de produção de anticorpos biespecíficos e de determinação de combinação, anticorpo biespecífico, formulação e uso de anticorpo biespecífico
CL2016001102A1 (es) Anticuerpos anti-claudina novedosos y métodos de uso.
CL2016001556A1 (es) Anticuerpos anti-cd3 y métodos de uso
CL2015000092A1 (es) Oligonucleótidos quiralmente controlados, composición que los comprende; método de elaboración: y uso para tratar cáncer.
CL2014003339A1 (es) Anticuerpo humanizado anti-trka con propiedades inhibitorias mejoradas; composición que lo comprende; y uso para tratar el dolor.
CL2015001266A1 (es) Anticuerpos de antihemaglutinina y métodos de uso.
BR112014028366A2 (pt) anticorpos anti-ly6e e imunoconjugados e métodos de uso
CL2014001640A1 (es) Composiciones y metodos para anticuerpos dirigidos factor de p; y usos del anticuerpo.
CL2015002829A1 (es) Anticuerpos biespecíficos específicos para fap y dr5, anticuerpos específicos para dr5 y métodos de utilización
BR112013013781A2 (pt) anticorpos humanizados para liv-1 e uso dos mesmos para tratar câncer
BR112015003938A2 (pt) métodos de produção de polipeptídeos, de produção de aglutinantes multiespecíficos, de seleção de aglutinantes multiespecíficos, de seleção de anticorpos biespecíficos e de determinação de combinação, anticorpo biespecífico, formulação farmcêutica e uso de anticorpo biespecífico
CL2013000930A1 (es) Anticuerpo para interleuquina 17 (il-17); uso de dicho anticuerpo para tratar soriasis usando antagonistas de il-17.
CO6831975A2 (es) Inmunoconjugados, composiciones para prepararlos, métodos para prepararlos y uso
CL2015002357A1 (es) Nuevos conjugados de anticuerpos y usos de los mismos
HRP20190516T1 (hr) Molekula protutijela protiv pd-1 i njihove uporabe
CO6900118A2 (es) Métodos para tratar el cancer por el uso de antagonistas de unión al eje pd-1e inhibidores de mek
CL2015001055A1 (es) Composiciones para lavado de ropa; y uso de dicha composicion.
BR112014005746A2 (pt) tecidos engendrados para usos em pesquisa in vitro, arranjos destes, e métodos de fabricar os mesmos
CO7000747A2 (es) Anticuerpos anti-lrp5 y métodos de uso
BR112016005594A2 (pt) Uso de ácido poliaspártico modificado, e, composição detergente para lavagem de louça
BR112014027544A2 (pt) composição cosmética, processo cosmético e uso cosmético.
MX2016005956A (es) Anticuerpos especificos para fcrn.
CL2015002724A1 (es) Métodos para tratar la enfermedad de crohn utilizando un anticuerpo anti-il23